tiprankstipranks
AlloVir downgraded to Underweight from Equal Weight at Morgan Stanley
PremiumThe FlyAlloVir downgraded to Underweight from Equal Weight at Morgan Stanley
4M ago
Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
PremiumThe Fly
Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
5M ago
AlloVir downgraded to Underperform from Buy at BofA
PremiumThe Fly
AlloVir downgraded to Underperform from Buy at BofA
5M ago
AlloVir downgraded to Neutral from Overweight at Piper Sandler
PremiumThe FlyAlloVir downgraded to Neutral from Overweight at Piper Sandler
5M ago
AlloVir downgraded to Underweight from Overweight at JPMorgan
PremiumThe Fly
AlloVir downgraded to Underweight from Overweight at JPMorgan
5M ago
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
PremiumPress Releases
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
5M ago
AlloVir initiated with a Buy at BofA
PremiumThe FlyAlloVir initiated with a Buy at BofA
9M ago
AlloVir initiated with a Buy at BofA
PremiumThe Fly
AlloVir initiated with a Buy at BofA
9M ago
AlloVir reports Q2 EPS (48c), consensus (44c)
PremiumThe Fly
AlloVir reports Q2 EPS (48c), consensus (44c)
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100